IMMUNIC, INC. (IMUX)
$15.42-$0.90 (-5.52%) Today
Latest IMUX Insider Trades
Daniel Vitt - OfficerOpen-market purchase$12K
Daniel Vitt - OfficerImmunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 16 | 1,273,180 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
44 Form 4 filings on record, the earliest from Nov 13, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Elena Ridloff - Director | Grant or award | Stock Option | 50,740 | $0.00 | - | |
| Simona Skerjanec - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Richard Alan Rudick - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Barclay A. Phillips - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Joerg Neermann - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
 Jon Congleton - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Jon Congleton - Director | Grant or award | Stock Option | 50,740 | $0.00 | - | |
| Simona Skerjanec - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Richard Alan Rudick - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Tamar D. Howson - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Joerg Neermann - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Barclay A. Phillips - Director | Grant or award | Stock Option | 25,370 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Option | 253,000 | $0.00 | - | |
 Glenn Whaley - Officer | Grant or award | Stock Option | 120,000 | $0.00 | - | |
| Daniel Vitt - Director | Grant or award | Stock Option | 445,000 | $0.00 | - | |
| Michael W. Bonney - Director | Grant or award | Stock Option | 100,000 | $0.00 | - | |
| Erik Lundgren - Officer | Grant or award | Stock Option | 1,000,000 | $0.00 | - | |
| Michael A. Panzara - Officer | Grant or award | Stock Option | 300,000 | $0.00 | - | |
| Duane Nash - Officer | Grant or award | Stock Appreciation Right | 315,000 | $0.00 | - | |
| Duane Nash - Officer | Grant or award | Stock Appreciation Right | 630,000 | $0.00 | - | |
| Duane Nash - Officer | Grant or award | Stock Appreciation Right | 630,000 | $0.00 | - | |
| Duane Nash - Officer | Grant or award | Stock Appreciation Right | 315,000 | $0.00 | - | |
| Duane Nash - Officer | Grant or award | Stock Appreciation Right | 315,000 | $0.00 | - | |
| Glenn Whaley - Officer | Grant or award | Stock Appreciation Right | 280,000 | $0.00 | - | |
| Glenn Whaley - Officer | Grant or award | Stock Appreciation Right | 560,000 | $0.00 | - | |
| Glenn Whaley - Officer | Grant or award | Stock Appreciation Right | 560,000 | $0.00 | - | |
| Glenn Whaley - Officer | Grant or award | Stock Appreciation Right | 280,000 | $0.00 | - | |
| Glenn Whaley - Officer | Grant or award | Stock Appreciation Right | 280,000 | $0.00 | - | |
 Andreas Muehler - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Andreas Muehler - Officer | Grant or award | Stock Appreciation Right | 660,000 | $0.00 | - | |
| Andreas Muehler - Officer | Grant or award | Stock Appreciation Right | 660,000 | $0.00 | - | |
| Andreas Muehler - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Andreas Muehler - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Daniel Vitt - Officer | Grant or award | Stock Appreciation Right | 860,000 | $0.00 | - | |
| Daniel Vitt - Officer | Grant or award | Stock Appreciation Right | 1,720,000 | $0.00 | - | |
| Daniel Vitt - Officer | Grant or award | Stock Appreciation Right | 1,720,000 | $0.00 | - | |
| Daniel Vitt - Officer | Grant or award | Stock Appreciation Right | 860,000 | $0.00 | - | |
| Daniel Vitt - Officer | Grant or award | Stock Appreciation Right | 860,000 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Appreciation Right | 660,000 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Appreciation Right | 660,000 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Jason Tardio - Officer | Grant or award | Stock Appreciation Right | 330,000 | $0.00 | - | |
| Daniel Vitt - Officer | Open-market purchase | Common Stock | 15,000 | $7.70 | $12K | |
| Daniel Vitt - Officer | Grant or award | Stock Option | 1,558,000 | $0.00 | - | |
| Duane Nash - Officer | Open-market purchase | Common Stock | 20,000 | $8.35 | $17K | |
| Joerg Neermann - Director | Open-market purchase | Common Stock | 70,000 | $7.70 | $54K | |
| Joerg Neermann - Director | Open-market purchase | Common Stock | 30,000 | $7.60 | $23K | |
| Monika Maria Toernsen - Director | Grant or award | Stock Option | 150,000 | $0.00 | - | |
| Tamar D. Howson - Director | Grant or award | Stock Option | 150,000 | $0.00 | - | |
| Barclay A. Phillips - Director | Grant or award | Stock Option | 150,000 | $0.00 | - | |
| Joerg Neermann - Director | Grant or award | Stock Option | 150,000 | $0.00 | - |
IMMUNIC, INC. (IMUX) had 16 insider filings in the last 90 days, with the most recent on 2026-08-10. The full record for IMUX runs to 44 Form 4 filings, the earliest from 2024-11-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IMUX were filed in the last 90 days. 8 purchases are on record for this company.
No insider sales of IMUX were filed in the last 90 days.
This page tracks IMUX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IMUX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
